Terms: = Skin cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568
1588 results:
1. Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) - Lifileucel (Amtagvi).
Parums DV
Med Sci Monit; 2024 May; 30():e944927. PubMed ID: 38689550
[TBL] [Abstract] [Full Text] [Related]
2. [Effect of Low-Dose Recombinant Interleukin-2 Therapy on Immunocyte Subsets in Children with Solid Tumor].
Lei JY; Li Y; Li CM; Xiong XL; Feng CC; Weng WJ; Peng XM; Zhou DH; Huang K
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):445-449. PubMed ID: 38660850
[TBL] [Abstract] [Full Text] [Related]
3. Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics.
Phoon YP; Lopes JE; Pfannenstiel LW; Marcela Diaz-Montero C; Tian YF; Ernstoff MS; Funchain P; Ko JS; Winquist R; Losey HC; Melenhorst JJ; Gastman BR
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604813
[TBL] [Abstract] [Full Text] [Related]
4. Oncolytic herpes simplex virus expressing il-2 controls glioblastoma growth and improves survival.
Bommareddy PK; Wakimoto H; Martuza RL; Kaufman HL; Rabkin SD; Saha D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38599661
[TBL] [Abstract] [Full Text] [Related]
5. Is There a Current Role for Combination Chemotherapy or High-Dose Interleukin 2 in Melanoma?
Fishman J; Buchbinder EI
Cancer J; 2024 Mar-Apr 01; 30(2):120-125. PubMed ID: 38527266
[TBL] [Abstract] [Full Text] [Related]
6. Quercetin Limits Tumor Immune Escape through PDK1/CD47 Axis in Melanoma.
Li X; He X; Lin B; Li L; Deng Q; Wang C; Zhang J; Chen Y; Zhao J; Li X; Li Y; Xi Q; Zhang R
Am J Chin Med; 2024; 52(2):541-563. PubMed ID: 38490807
[TBL] [Abstract] [Full Text] [Related]
7. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
[TBL] [Abstract] [Full Text] [Related]
8. Interleukin-2-induced skin inflammation.
Sommer C; Cohen JN; Dehmel S; Neuhaus V; Schaudien D; Braun A; Sewald K; Rosenblum MD
Eur J Immunol; 2024 Apr; 54(4):e2350580. PubMed ID: 38430129
[TBL] [Abstract] [Full Text] [Related]
9. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
[TBL] [Abstract] [Full Text] [Related]
10. Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma.
Zhang W; Wang S
Melanoma Res; 2024 Jun; 34(3):215-224. PubMed ID: 38364052
[TBL] [Abstract] [Full Text] [Related]
11. Regulatory T cells in skin mediate immune privilege of the hair follicle stem cell niche.
Cohen JN; Gouirand V; Macon CE; Lowe MM; Boothby IC; Moreau JM; Gratz IK; Stoecklinger A; Weaver CT; Sharpe AH; Ricardo-Gonzalez RR; Rosenblum MD
Sci Immunol; 2024 Jan; 9(91):eadh0152. PubMed ID: 38181095
[TBL] [Abstract] [Full Text] [Related]
12. NK cells propagate T cell immunity following in situ tumor vaccination.
Jin WJ; Jagodinsky JC; Vera JM; Clark PA; Zuleger CL; Erbe AK; Ong IM; Le T; Tetreault K; Berg T; Rakhmilevich AL; Kim K; Newton MA; Albertini MR; Sondel PM; Morris ZS
Cell Rep; 2023 Dec; 42(12):113556. PubMed ID: 38096050
[TBL] [Abstract] [Full Text] [Related]
13. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.
Jedlowski PM; DuPont JP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):937-944. PubMed ID: 38071595
[TBL] [Abstract] [Full Text] [Related]
14. Celastrol, which targets il-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma.
Cho O; Lee JW; Jeong YJ; Kim LK; Jung BK; Heo TH
Eur J Pharmacol; 2024 Jan; 962():176239. PubMed ID: 38043776
[TBL] [Abstract] [Full Text] [Related]
15. Signaling via a CD28/CD40 chimeric costimulatory antigen receptor (CoStAR™), targeting folate receptor alpha, enhances T cell activity and augments tumor reactivity of tumor infiltrating lymphocytes.
Kalaitsidou M; Moon OR; Sykorova M; Bao L; Qu Y; Sukumaran S; Valentine M; Zhou X; Pandey V; Foos K; Medvedev S; Powell DJ; Udyavar A; Gschweng E; Rodriguez R; Dudley ME; Hawkins RE; Kueberuwa G; Bridgeman JS
Front Immunol; 2023; 14():1256491. PubMed ID: 38022678
[TBL] [Abstract] [Full Text] [Related]
16. Correlations between inflammatory cytokine levels and degree of pigmentation in acral melanomas.
Kim HE; Kim J; Park HK; Lee JB; Yun SJ
Melanoma Res; 2024 Feb; 34(1):38-43. PubMed ID: 37924528
[TBL] [Abstract] [Full Text] [Related]
17. In vitro modelling of local gene therapy with IL-15/IL-15Rα and a PD-L1 antagonist in melanoma reveals an interplay between NK cells and CD4
Awad RM; De Vlaeminck Y; Meeus F; Ertveldt T; Zeven K; Ceuppens H; Goyvaerts C; Verdonck M; Salguero G; Raes G; Devoogdt N; Breckpot K
Sci Rep; 2023 Nov; 13(1):18995. PubMed ID: 37923822
[TBL] [Abstract] [Full Text] [Related]
18. Antitumor Immune Responses in B2M-Deficient cancers.
Torrejon DY; Galvez M; Abril-Rodriguez G; Campbell KM; Medina E; Vega-Crespo A; Kalbasi A; Comin-Anduix B; Ribas A
Cancer Immunol Res; 2023 Dec; 11(12):1642-1655. PubMed ID: 37801341
[TBL] [Abstract] [Full Text] [Related]
19. Tumor-Targeted Delivery of il-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy.
Chu T; Cao B; Wang P; Li B; Ren J; Nie G; Wei J; Li S
Bioconjug Chem; 2023 Oct; 34(10):1894-1901. PubMed ID: 37787935
[TBL] [Abstract] [Full Text] [Related]
20. Tumor-infiltrating lymphocyte transfusion in a patient with treatment refractory triple negative breast cancer.
Jacover A; Zarbiv Y; Tal KH; Klein S; Breuer S; Durst R; Avni B; Grisariu S; Stepensky P; Lotem M; Maimon O; Yablonski-Peretz T
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1894. PubMed ID: 37750497
[TBL] [Abstract] [Full Text] [Related]
[Next]
